Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Retatrutide vs Orforglipron

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Orforglipron has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Retatrutide

Phase 3

Orforglipron

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Retatrutide Orforglipron
Class GIP/GLP-1/glucagon triple agonist Oral non-peptide GLP-1 agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14]
Route SC injection Oral
Half-life ~6 days ~29-49 hrs
Dosage (research) 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15]
Evidence tier Phase 3 FDA-Approved
Research depth 217 indexed (PubMed 159 · CT 33 · EPMC 25) 197 indexed (PubMed 131 · CT 54 · EPMC 12)
Availability Investigational Prescription
Reported risks GI side effects; Phase 3 ongoing; long-term safety unknown GI effects; hepatic enzyme elevations

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Retatrutide or Orforglipron?

Orforglipron has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Retatrutide and Orforglipron?

Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Retatrutide, ~6 days; Orforglipron, ~29-49 hrs. Routes in published studies: Retatrutide, SC injection; Orforglipron, Oral.

Which has stronger evidence, Retatrutide or Orforglipron?

Orforglipron has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.

Which is more accessible, Retatrutide or Orforglipron?

Orforglipron is FDA-approved and Retatrutide is not. Catalog status: Retatrutide, Investigational; Orforglipron, Prescription.

Are Retatrutide and Orforglipron ever combined?

Retatrutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…